ATTR-CM is a heart disease that is often undiagnosed and can be fatal. Dr. James Ampadu, a cardiologist with Prisma Health, shares symptoms of ATTR-CM. Ian, who was diagnosed with ATTR-CM, also shares ...

GlobalData estimates that vutrisiran’s entrance into the ATTR-wt market will change the treatment paradigm.

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...

ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup ...

The drug, branded as Attruby in the U.S. and BEYONTTRA in Europe, showed rapid and sustained benefits for both variant and wild-type ATTR-CM patients, with noticeable improvements as early as ...

BridgeBio Pharma announced promising results from its Phase 3 trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM), revealing that early and sustained increases in serum ...